Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246519 · ClinicalTrials.gov registry record · Phase 4
Pharmacogenomic Evaluation of Antihypertensive Responses
A Phase 4 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,701
- Enrollment target
NCT00246519: Completed Phase 4 study, sponsored by University of Florida.
NCT00246519 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 1,701 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (228% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00246519, a Phase 4 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,701 participants
- Enrollment target
Study Summary
There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that only 34% of people with hypertension have their blood pressure under control. The hypothesis is that genetic differences between individuals influence their response to antihypertensive medications. This study is aimed at determining the genetic factors that may influence a person's response to either a beta-blocker or a thiazide diuretic. The hope is that through this research, we may someday be able to use an individual's genetic information to guide the selection of their blood pressure medicine, leading to better control of blood pressure, and less need for the current trial and error process.
Interventions
- DRUG Atenolol
- DRUG Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,701 participants |
| Start Date | 2005-10 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
What the finished NCT00246519 record still lists
NCT00246519 is an interventional study that assigns participants to a tested intervention. Its 1,701 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (228% higher).
The record links to 0 conditions, and to 2 interventions - of which Atenolol is the first listed.
NCT00246519 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00246519 about?
NCT00246519 is a clinical study titled "Pharmacogenomic Evaluation of Antihypertensive Responses". There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that only 34% of people with hypertension have their blood pressure under control. The hypothesis is that geneti...
What is the current status of trial NCT00246519?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,701 participants. The study started on 2005-10. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00246519?
The interventions under investigation include: Atenolol (DRUG), Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00246519?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00246519's enrollment target sits among peer trials
1,701 47th of 2000 higher than 1,954 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
- NCT06238622 · 1,700 participants · Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- NCT07284901 · 1,700 participants · Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia